Articles

Merck stops Alzheimer’s study after ‘no chance’ of benefit

Merck & Co. on Tuesday announced that it will end a study of its once-promising Alzheimer’s disease drug in patients with mild-to-moderate forms of the condition, just three months after Eli Lilly and Co. announced its own setback in a field that’s been littered with failures.

Read More

Aetna gives up on $34B Humana deal, will pay $1B breakup fee

The Humana-Aetna deal was one of two mergers that would have reshaped the U.S. health insurance landscape. Both were rejected by federal judges as anticompetitive. Anthem hasn't given up on its deal—a $48 billion pact to acquire Cigna—and is pressing ahead with an appeal.

Read More

Dealmakers wonder if Trump will intervene in mergers

It wasn’t a surprise when Donald Trump took the opportunity during his Jan. 11 press conference to angrily accuse CNN of spreading fake news. Throughout the campaign Trump had complained the cable network was being unfair to him—and at one point vowed that as president, he would block AT&T Inc.’s proposed $85.4 billion merger with […]

Read More